Find the latest clinical trials by condition, location & phase
Browse and search for drug information and related clinical trials
Explore a comprehensive list of organizations, including their profiles and details.
Latest updates on clinical trials, pharmaceuticals, and healthcare companies
Stay informed with timely notifications on clinical trials and research advancements.
No overview information available.
No background information available.
No indication information available.
No associated conditions information available.
OKYO Pharma expects to complete enrollment of 48 patients in its Phase 2a trial of OK-101, the first FDA-cleared investigational drug specifically for neuropathic corneal pain, by Q2 2025.
OKYO Pharma has dosed the first subject in its Phase II clinical trial of OK-101 for neuropathic corneal pain (NCP).
OKYO Pharma has dosed the first patient in its Phase 2 clinical trial evaluating OK-101 for the treatment of neuropathic corneal pain (NCP).